Our portfolio includes Long Acting Beta Agonists(LABA) and Inhaled Cortico Steroids(ICS) in different strengths and combinations to enable step-up or step-down asthma treatment regimes.
For more extreme conditions, our development includes Inhaled Long-Acting Muscarinic Antagonists(LAMAs) for COPD.
Respirent is exploring new and innovative ways to improve the delivery and effectiveness our medicines to benefit our customers.